On June 7, 2017 Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company, reported that based upon promising early evidence of anti-tumor activity in patients with both myeloid and lymphoid malignancies, it has further expanded its current intravenous dosing trial of TTI-621, an IgG1 SIRPaFc fusion protein targeting CD47 (Press release, Trillium Therapeutics, JUN 7, 2017, View Source [SID1234519464]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Changes to the trial include:

An additional cohort of patients with Hodgkin lymphoma treated with a combination of TTI-621 and the PD-1 checkpoint inhibitor nivolumab
Two additional cohorts of patients with T- and B-cell acute lymphoblastic leukemia and small cell lung cancer treated with TTI-621 monotherapy
Cautious exploration of dose-intensification, building upon the observation of good overall tolerability associated with attenuated thrombocytopenia over successive weekly doses of TTI-621
Increasing the size of cohorts exhibiting early evidence of clinical benefit
"Having observed meaningful objective responses among multiple treatment-refractory cancer patients, we are now expanding the trial’s scope with additional focused enrollment to extend these preliminary observations and to seek promising new signals of activity—both with TTI-621 monotherapy, with rituximab, and in a novel combination with T-cell checkpoint inhibition," said Trillium’s Chief Medical Officer, Dr. Eric Sievers. "With emerging data linking CD47 blockade with T cell activation, we are excited to pursue the combination of TTI-621 and nivolumab in an attempt to optimally engage both the innate and adaptive arms of the immune system to generate a robust and enduring anti-tumor response."